肿瘤细胞治疗研究
英文原题：The Bidirectional Interplay between T Cell-Based Immunotherapies and the Tumor Microenvironment.
基于T细胞的疗法，包括TIL（肿瘤浸润淋巴细胞）疗法、T细胞受体工程化T细胞和CAR-T 细胞，是治疗癌症的强大治疗方法。
基于T细胞的疗法，包括TIL（肿瘤浸润淋巴细胞）疗法、T细胞受体工程化T细胞和CAR-T 细胞，是治疗癌症的强大治疗手段。尽管这些疗法主要以对癌细胞的直接细胞毒性作用而闻名，但越来越多的证据表明，它们还通过改变细胞因子环境和招募额外的效应细胞群来帮助协调抗肿瘤免疫反应，从而影响肿瘤微环境（TME）。相反，TME本身可以通过支持或抑制这些疗法在宿主体内的活性来调节其行为。在这篇综述中，我们概述了关于T细胞疗法与TME之间双向影响的临床和临床前数据。揭示基于T细胞的疗法与TME之间的相互作用对于更好地理解其作用机制、耐药性和毒性至关重要，目的是优化疗效和安全性。
T cell-based therapies, including tumor-infiltrating lymphocyte therapy, T-cell receptor-engineered T cells, and chimeric antigen receptor T cells, are powerful therapeutic approaches for cancer treatment. Whereas these therapies are primarily known for their direct cytotoxic effects on cancer cells, accumulating evidence indicates that they also influence the tumor microenvironment (TME) by altering the cytokine milieu and recruiting additional effector populations to help orchestrate the antitumor immune response. Conversely, the TME itself can modulate the behavior of these therapies within the host by either supporting or inhibiting their activity. In this review, we provide an overview of clinical and preclinical data on the bidirectional influences between T-cell therapies and the TME. Unraveling the interactions between T cell-based therapies and the TME is critical for a better understanding of their mechanisms of action, resistance, and toxicity, with the goal of optimizing efficacy and safety.
MEMBER ACCOUNT
登录成功会直接打开下一页。
